In a recent of analysis of TP53 mutations in 506 de novo R-CHOP-treated DLBCL, 21.9% had mutations in TP53 and the presence of a mutation was associated with both overall survival and progression-free survival. This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.